摘要瑞芬太尼痛觉过敏的发生,是一个多机制参与、多种生理生化反应依次发生的过程,确切机制未清。本文综述参与瑞芬太尼痛觉过敏发生的受体机制及其下游信号通路机制,包括α7-n Ach Rs受体、趋化因子受体等新的相关受体。从受体角度探究瑞芬太尼痛觉过敏的发生,为治疗瑞芬太尼痛觉过敏的有效分子靶点提供理论支持。
3Powell KJ,Abul-Husn NS,Jnamandas A,et al. Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance, and reward in rats. J Pharmacol Exp Ther, 2002,300 : 588-596.
4Hahnenkamp K, Nollet J, Van Aken HK, et al. Remifentanil directly activates human N-methyl-D-aspartate receptors expressed in Xenopus laevis oocytes. Anesthesiology ,2004,100 : 1531-1537.
5Albrecht S, Feehner J, Geisslinger G, et al. Postoperative pain control following remifentanil-based anesthesia for major abdominal surgery. Anaesthsia,2000,55:315-322.
6Cart RM, Bernal SA. Sex differences in opioid antinociception: kappa and "mixed action" agonists. Drug Alcohol Depend ,2001, 63:215-228.
7Angst MS, Koppert W, Pahl I, et al. Short-term infusion of the mu- opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain ,2003,106:49-57.
